Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $27.39 USD
Change Today +0.22 / 0.81%
Volume 125.1K
OTIC On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:16 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

otonomy inc (OTIC) Snapshot

Open
$27.20
Previous Close
$27.17
Day High
$28.58
Day Low
$26.80
52 Week High
03/11/15 - $41.99
52 Week Low
08/19/14 - $15.19
Market Cap
661.0M
Average Volume 10 Days
177.4K
EPS TTM
$-5.46
Shares Outstanding
24.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OTONOMY INC (OTIC)

Related News

No related news articles were found.

otonomy inc (OTIC) Related Businessweek News

No Related Businessweek News Found

otonomy inc (OTIC) Details

Otonomy, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear in the United States and Canada. Its lead product candidate is AuriPro, a sustained-exposure antibiotic, which completed Phase III clinical trials to treat pediatric patients with middle ear effusion or fluid at the time of tympanostomy tube placement surgery. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone that is in a Phase IIb clinical trial for the treatment of patients with Ménière’s disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in preclinical development as a potential treatment for tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

38 Employees
Last Reported Date: 03/18/15
Founded in 2008

otonomy inc (OTIC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $692.7K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $471.7K
Chief Commercial Officer
Total Annual Compensation: $68.5K
Chief Scientific Officer
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2014.

otonomy inc (OTIC) Key Developments

Otonomy, Inc. Appoints George J. Morrow to the Board of Directors

Otonomy, Inc. announced the appointment of George J. Morrow to the board of directors. Mr. Morrow brings more than 30 years of experience in pharmaceutical commercial operations for leading pharmaceutical companies including Amgen, GlaxoSmithKline and Merck. From 2003 until his retirement in 2011, Mr. Morrow served as executive vice president, global commercial operations at Amgen where he was responsible for commercial and government affairs activities across 50 countries including the United States. Mr. Morrow led global commercial operations for Amgen for nearly a decade overseeing commercial and government affairs activities across 50 countries, and continued to serve as a consultant to the company following his retirement. Prior to his retirement Mr. Morrow held the role of executive vice president, global commercial operations, and prior to this position he was the executive vice president of worldwide sales and marketing. Mr. Morrow currently serves on the board of directors of Vical Incorporated and Align Technology, Inc. He previously served on the board of directors of Safeway Inc.

Otonomy, Inc. Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients

Otonomy, Inc. announced that it has achieved target enrollment in its multiple-dose safety study of OTO-104 in patients with Ménière's disease. This prospective, randomized, placebo-controlled study, designed to evaluate the safety of quarterly dosing of OTO-104, enrolled a total of 128 patients across multiple trial sites in the United Kingdom. In the first part of this multiple-dose safety study, patients are randomized to receive two doses of either placebo or 12 mg OTO-104 by intratympanic (IT) injection given at quarterly intervals. Patients completing the double-blind portion of the study will receive two IT injections of OTO-104 at quarterly intervals. Each enrolled patient is expected to participate in the study for a total of one year.

Otonomy, Inc. Appoints Dean Hakanson as Chief Medical Officer

Otonomy, Inc. announced the appointment of Dean Hakanson, M.D., as chief medical officer. Dr. Hakanson has more than 16 years of industry experience in medical affairs, market access and health economic research with leading pharmaceutical companies including Novartis, Bristol-Myers Squibb, Genentech and GlaxoSmithKline.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OTIC:US $27.39 USD +0.22

OTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OTIC.
View Industry Companies
 

Industry Analysis

OTIC

Industry Average

Valuation OTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OTONOMY INC, please visit www.otonomy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.